Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia by Clark, Richard E et al.
   
 
Article 
Validation of CIP2A as a Biomarker of Subsequent Disease  
Progression and Treatment Failure in Chronic Myeloid  
Leukaemia 
Richard E. Clark 1, Ammar A. Basabrain 1, Gemma M. Austin 1, Alison K. Holcroft 1, Sandra Loaiza 2, Jane F. Apperley 3, 
Christopher Law 4, Laura Scott 1, Alexandra D. Parry 5, Laura Bonnett 6 and Claire M. Lucas 1,5,* 
1 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK; 
clarkre@liverpool.ac.uk (R.E.C.); a.a.basabrain@liverpool.ac.uk (A.A.B.); gemmajon2003@yahoo.co.uk 
(G.M.A.); alisonkholcroft@hotmail.co.uk (A.K.H.); l.scott1@liverpool.ac.uk (L.S.) 
2 The John Goldman Centre for Cellular Therapy, Hammersmith Hospital, Imperial College Healthcare NHS 
Trust, London W12 0HS, UK; sandra.loaiza@nhs.net 
3 Centre for Haematology, Imperial College London at Hammersmith Hospital, London W12 0HS, UK; 
j.apperley@imperial.ac.uk 
4 Technology Directorate, University of Liverpool, Liverpool L69 3GA, UK; K.C.Law@liverpool.ac.uk 
5 Chester Medical School, University of Chester, Bache Hall, Chester CH2 1BR, UK; 1711962@chester.ac.uk6
 Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, UK; L.J.Bonnett@liverpool.ac.uk 
* Correspondence: c.lucas@chester.ac.uk 
Simple Summary: Tyrosine kinase inhibitor treatment has greatly improved the prognosis for many 
chronic myeloid leukaemia patients; however, disease progression is usually fatal for patients and 
remains a significant clinical challenge today. Using the U.K. SPIRIT 2 (STI571 Prospective 
International RandomIsed Trial 2) clinical trial, we have validated cancerous inhibitor of protein 
phosphatase 2A (PP2A) (CIP2A) as a diagnostic biomarker to identify patients at risk of disease 
progression and treatment failure. CIP2A is a simple diagnostic biomarker that may be a useful 
diagnostic tool in planning treatment strategies. 
Abstract: Background: It would be clinically useful to prospectively identify the risk of disease 
progression in chronic myeloid leukaemia (CML). Overexpression of cancerous inhibitor of protein 
phosphatase 2A (PP2A) (CIP2A) protein is an adverse prognostic indicator in many cancers. 
Methods: We examined CIP2A protein levels in diagnostic samples from the SPIRIT2 trial in 172 
unselected patients, of whom 90 received imatinib and 82 dasatinib as first-line treatment. Results: 
High CIP2A levels correlated with inferior progression-free survival (p = 0.04) and with worse 
freedom from progression (p = 0.03), and these effects were confined to dasatinib recipients. High 
CIP2A levels were associated with a six-fold higher five-year treatment failure rate than low CIP2A 
levels (41% vs. 7.5%; p = 0.0002), in both imatinib (45% vs. 11%; p = 0.02) and dasatinib recipients 
(36% vs. 4%; p = 0.007). Imatinib recipients with low CIP2A levels had a greater risk of treatment 
failure (p = 0.0008). CIP2A levels were independent of Sokal, Hasford, EUTOS (EUropean 
Treatment and Outcome Study), or EUTOS long-term survival scores (ELTS) or the presence 
of major route cytogenetic abnormalities. No association was seen between CIP2A levels and time 
to molecular response or the levels of the CIP2A-related proteins PP2A, SET, SET binding protein 1 
(SETBP1), or AKT. Conclusions: These data confirm that high diagnostic CIP2A levels correlate with 
subsequent disease progression and treatment failure. CIP2A is a simple diagnostic biomarker 
that may be useful in planning treatment strategies. 





Tyrosine kinase inhibitors (TKIs) have transformed the clinical landscape for patients 
with chronic-phase chronic myeloid leukaemia (CML), with life expectancy essentially 
normal for about 90% of patients. However, TKIs do not offer a cure, as they do not 
eradicate leukaemic stem cells (LSC) [1-3]. Furthermore, a proportion of patients will 
progress to blast crisis, with a median survival of approximately 10 months 4. Disease 
progression to accelerated phase is defined by the European Leukemia Net (ELN) as a 
blast count >15% and blast crisis is >30% 5, 6. Various scoring systems have been developed 
to prospectively identify patients at high risk of transformation 7-9, but Italian data on the 
long-term outcome of imatinib treatment suggest that >70% of patients identified as high 
risk by Sokal or other scores may remain well at 7 years [10] precluding the use of these 
scoring systems to influence treatment decisions. More recently, the EUTOS long-term 
survival score (ELTS) has been developed to look at the risk of disease progression to the 
advanced phase, but again even patients in the high-risk ELTS group had an 8-year 
incidence of death from CML of only 11% 11. Similarly, the German/Swiss CML IV study 
has identified that certain additional chromosomal abnormalities (ACA) beyond a single 
Philadelphia (Ph) translocation may confer a six-fold increased risk of disease progression 
12, but ACA are only present in ~3% of patients, and also these findings have yet to be 
confirmed in other studies. There is, therefore, a need for a reliable prospective biomarker 
of disease progression to blast crisis. 
Protein phosphatase 2A (PP2A) is a phosphatase that is important in opposing the 
overactive kinases that typify many malignancies; it is thus a tumour suppressor. PP2A 
inactivation is an essential requirement for transforming human cells 13. PP2A is regulated 
by numerous inhibitor proteins such as a Cancerous Inhibitor of PP2A (CIP2A) 14, SET 15, 
and SET binding protein 1 (SETBP1) 16, and expression of these inhibitor proteins can vary 
between malignancies and even within malignancy sub-types. For example, acute 
myeloid leukaemia (AML) patients with normal karyotype have their PP2A 
predominately inhibited by CIP2A, while patients with an adverse karyotype have their 
PP2A inhibited by SETBP1 17. Both SETBP1 and CIP2A inhibit PP2A, resulting in 
phosphorylation of the serine/threonine kinase AKT (also known as protein kinase B) at 
its S473 residue 17, and this leads to uncontrolled cell proliferation and resistance to 
apoptosis, both hallmarks of oncogenic transformation 18. 
We reported in 2011 that at initial diagnosis of chronic-phase CML, imatinib 
recipients with high levels of CIP2A protein had a high actuarial risk of progression to 
blast crisis, and this was not associated with BCR-ABL1 kinase domain mutations 19. Over 
150 clinical papers have subsequently confirmed that high CIP2A levels are associated 
with adverse histology and/or poor response to treatment in over 20 different cancer 
histologies 20-26, including AML 17. Our group subsequently showed that patients with high 
CIP2A levels who received front-line treatment with the second generation (2G) TKIs 
dasatinib or nilotinib did not have this high progression risk, suggesting that CIP2A might 
be a useful biomarker to identify a group of patients who might be better treated with a 
2G TKI 27. However, our studies were limited to 74 patients in whom disease progression 
was overrepresented but confined to imatinib recipients; indeed, no samples were 
available at our institution from front-line dasatinib or nilotinib recipients that underwent 
progression. It is therefore important to validate our findings in an independent and 
larger cohort more representative of everyday CML practice. Therefore, we investigated 
the prospective value of assessing CIP2A and related proteins at diagnosis in a subset of 
172 patients enrolled in the United Kingdom SPIRIT2 trial, a phase 3 study comparing 
imatinib and dasatinib for first-line treatment in newly diagnosed chronic-phase CML 
patients. The principal findings from SPIRIT2 have been presented 28. 
  
 
2. Materials and Methods 
2.1. Patients 
In the SPIRIT2 trial, 814 newly diagnosed chronic-phase patients were randomly 
allocated 1:1 to either imatinib 400 mg or dasatinib 100 mg each once daily. Follow-up was 
monthly for 3 months, 3-monthly until 12 months, then 6-monthly. Patients were followed 
until the sooner of 5 years or a change of therapy due to either intolerance or resistance 28. 
At each visit, a centralised molecular assessment of the BCR-ABL1/ABL1 ratio was carried 
out using International Standardisation (IS) at the Molecular Pathology Laboratory at the 
Imperial College Healthcare NHS Trust (ICHNT), London. Results with less than 10,000 
ABL1 control transcripts were rejected 29. 
The vast majority of SPIRIT2 entrants gave informed consent to donate samples to 
the SPIRIT2 biobank housed at ICHNT, in addition to the consent required to enter the 
trial. The present project was approved by the National Cancer Research Institute CML 
subgroup, who have ownership of this biobank, and ethical approval was given by the 
Liverpool East Committee of the U.K. National Research Ethics Committee. To maximise 
follow-up yet conserve resources, the study focused on the first available 200 (25%) 
diagnostic samples from the SPIRIT2 entrants plus all subsequent patients who 
progressed. This resulted in a total of 172 samples available/suitable for study, which 
included 18 of the 23 patients in the entire study who progressed to the advanced phase. 
2.2. Sample Collection and Preparation 
Peripheral blood mononuclear cells were separated from diagnostic samples by 
density-dependent centrifugation (Lymphoprep Axis-Shield, Cambridge, U.K.), washed 
in RPMI 1640 (BioSera, Nuaille, France), and resuspended in 10% dimethylsulfoxide 
(DMSO)/10% fetal calf serum (FCS) (BioSera)/RPMI at 4 °C. Cells were then 
cryopreserved. Samples were thawed in RPMI containing 10% FCS and 1% L-glutamine 
using the dropwise method. 
2.3. Measurement of CIP2A and Associated Proteins 
The flow cytometry methodology has been previously described [17,19,27] and was 
used for the detection of CIP2A, SET, SETBP1, AKT, and AKTS473. The following antibodies 
were used: CIP2A, SET, SETBP1, AKT, and AKTS473 (all from Santa Cruz Biotechnology, 
California, USA), anti-mouse and anti-rabbit Alex Fluor 488 (Invitrogen, Paisley, U.K.), 
and CD45perCP (BD Bioscience, Oxford, U.K.). Samples were analysed by flow cytometry 
using a FACSCanto II machine (BD Bioscience, Oxford, U.K.), and the resultant data were 
analysed by FACS Diva software, version 8.0.1. 
2.4. Definitions of Outcome Endpoints 
Overall survival (OS) was defined as the time from trial entry to death from any 
cause. Progression-free survival (PFS) was defined as the time from trial entry to disease 
progression to advanced phase or death from any cause, whichever were the earlier. 
Freedom from progression (FFP) was defined as the time from trial entry to progression 
alone. Time to treatment failure was defined as the time from trial entry to a change in the 
allocated therapy because of resistance. 
2.5. Statistical Analysis 
The level of CIP2A was assigned as either high or low according to the maximally 
selected rank statistic, which is an outcome-oriented method providing a value of a cut 
point that corresponds to the most significant relationship with the outcome. In Kaplan–
Meier plots, p-values were determined using the log-rank (Mantel–Cox) test; where 




Patient characteristics for all 172 patients studied are shown in Table 1. Briefly, 90 
patients received imatinib, while 82 received dasatinib. Eighteen patients progressed to 
blast crisis (9 imatinib- and 9 dasatinib-treated patients). Overall, the median age was 52 
years, similar in each treatment arm, though 115 (66.9%) of the 172 patients were male, 
with 61.1% and 73.3% in the imatinib and dasatinib arms, respectively. 
Table 1. Patient characteristics table. 
Catergory Imatinib (90) Dasatinib (82) Total 
Median age (range) 52 (20–87) 55 (18–81) 52 (18–87) 
Sex - - - 
Male 55 60 115 
Female  35 22 57 
Sokal Score - - - 
Low 20 14 34 
Intermediate 16 22 38 
High 18 14 32 
N/A 36 32 68 
Hasford Score - - - 
Low 23 18 41 
Intermediate 15 18 33 
High 12 7 19 
N/A 40 39 79 
EUTOS - - - 
Low 73 58 131 
High 11 12 23 
N/A 6 12 18 
ELTS - - - 
Low 28 26 54 
Intermediate 14 14 28 
High 12 10 22 
N/A 36 32 68 
N/A = not available; other abbreviations as defined in the text. 
3.1. CIP2A and Established Scoring Sytems 
We first examined how the established scoring systems correlated to progression and 
to levels of CIP2A and its related proteins. Recording the components of the various 
scoring systems was not mandatory at trial entry; as a result, 39% (Sokal), 45% (Hasford), 
10% (EUTOS), and 39% (ELTS) of the present 172 patients could not be allocated a score. 
There was a non-significant trend for worse progression-free survival in patients with a 
high Sokal score (Figure 1a) and a similar trend for patients with high Sokal scores to have 
higher CIP2A protein levels (Figure 1b). The Hasford and EUTOS scores did not predict 
progression-free survival (consistent with the findings of both the Italian and German 
studies) [8,10] or correlate with CIP2A levels (Figures 1c–f). However, the ELTS score 
correlated with progression-free survival (Figure 1g; p = 0.01), consistent with a recent 
report [30], though no correlation was seen between it and CIP2A levels (Figure 1h). No 
association was found between diagnostic CIP2A levels and the presence of trisomy 8 or 
19, a second Ph translocation, or isochromosome 17 (Figure 1i). CIP2A protein levels are 






Figure 1. CIP2A protein level is independent of scoring systems and abnormal cytogenetics. Progression-free survival 
(PFS) and diagnostic CIP2A MNC protein levels stratified by Sokal score (a–b), Hasford score (c–d), EUTOS score (e–f), 
ELTS (g–h), and abnormal cytogenetics (i). 
3.2. High CIP2A Is Associated with an Inferior Progression-Free Survival 
The overall survival for these 172 patients is given in Figure S1, according to the 
patient’s CIP2A status and stratified by TKI received. No correlation is seen between the 
CIP2A level and overall survival. 
Figure 2a shows that a high CIP2A level is associated with inferior progression-free 
survival (p = 0.04). Figure 2b,c shows the progression-free survival for the imatinib and 
dasatinib recipients, respectively, and suggests that the trend toward inferior progression-
free survival with high CIP2A mostly derives from the dasatinib recipients, though 
numbers become too small to achieve statistical significance. However, the contribution 
of progression to progression-free survival is dominated by patients who died from 
causes unrelated to CML. In the present 172 patients, 27 deaths were observed, of which 
only 14 (51%) were CML-related. Therefore, in assessing the effect of CIP2A on 
progression, freedom from progression (FFP) may be more informative. This is shown in 
Figure 3, set out in the same way as Figure 2. As for progression-free survival, high CIP2A 
levels are associated with inferior freedom from progression (Figure 3a; p = 0.03, Fisher's 
exact test), and again this is mostly due to the dasatinib recipients (Figure 3c; p = 0.003, 
Fisher's exact test); no difference in freedom from progression according to CIP2A status 




Figure 2. Progression-free survival (PFS). Kaplan–Meier curves for progression-free survival, stratified by diagnostic 
CIP2A level for (a) all 172 patients, (b) imatinib recipients, and (c) dasatinib recipients. p-values were determined using 
the log-rank (Mantel–Cox) test; p-values are shown where significant. 
Overall, the risk of disease progression for patients with low and high CIP2A levels 
was 5% and 15%, respectively (Figure 3a), but this difference was particularly marked for 
dasatinib recipients (Figure 3c; 2% and 23%, respectively; p = 0.004), while not differing 
for imatinib recipients (Figure 3b; 9.5% and 10%, respectively). One dasatinib-treated 
patient with low CIP2A progressed; this patient had a high Sokal score and an 
intermediate ELTS score and frequent treatment interruptions due to recurrent pleural 
effusions. Four out of 42 imatinib recipients with low CIP2A progressed, and all four 
presented with intermediate (2 patients) or high (2 patients) Sokal and ELTS scores, and 3 
of the 4 had ACA at diagnosis (either trisomy 8, a second Ph, or isochromosome 17). The 
adverse cytogenetics and treatment interruption may have contributed to progression in 




Figure 3. Freedom from progression (FFP). Kaplan–Meier curves for freedom from progression, stratified by diagnostic 
CIP2A level for (a) all 172 patients, (b) imatinib recipients, and (c) dasatinib recipients. p-values were determined using 
the log-rank (Mantel–Cox) test; p-values are shown where significant. 
  
 
3.3. High CIP2A Is Associated with Treatment Failure 
We next investigated if the diagnostic CIP2A level was associated with treatment 
failure. Figure 4a shows that patients with high CIP2A levels were more likely to fail 
treatment (p = 0.001). When patients were stratified by TKI treatment, there was a trend 
for imatinib-treated patients with high CIP2A levels to have a higher failure rate than 
those with low levels. For dasatinib-treated patients, high CIP2A levels conferred a 
significantly higher risk of treatment failure (Figure 4c; p = 0.003). Patients with low CIP2A 
levels and treated with imatinib had an inferior treatment failure rate than dasatinib-
treated patients (Figure 4d; p = 0.0008). Patients with high CIP2A levels had a significant 
risk of failing treatment (p = 0.001); when we compared imatinib and dasatinib treatment 
for patients with high CIP2A levels, imatinib-treated patients had a trend for higher risk 
of treatment failure (Figure 4e). 
 
 
Figure 4. Time to treatment failure. Kaplan–Meier curves for time to treatment failure, stratified by diagnostic CIP2A level 
for (a) all 172 patients, (b) imatinib recipients, and (c) dasatinib recipients, (d) according to treatment received for patients 
with low CIP2A levels only, and (e) according to treatment received for patients with low CIP2A levels only. p-values 
were determined using log-rank (Mantel–Cox) test; p-values are shown where significant. 
Patients with a high CIP2A level at diagnosis had a 41% chance of treatment failure 
by 5 years, compared to 7.5% for patients with low CIP2A levels (p = 0.002, Fisher’s exact 
test). For imatinib-treated patients, the risk of treatment failure was 45% and 11% for the 
high and low CIP2A groups, respectively. (p = 0.02, Fisher’s exact test). For dasatinib-
treated patients, patients with high CIP2A levels had a 36% chance of treatment failure 
compared to 4% for those with low CIP2A levels (p = 0.007, Fisher’s exact test). High 
CIP2A levels at diagnosis thus predict a significant risk of treatment failure irrespective 
of TKI treatment. 
3.4. Time to Molecular Response 
Imatinib recipients with a high CIP2A level had a significantly worse early molecular 
response rate (defined as a BCR-ABL1/ABL1IS ratio of ≤ 10% at 3 months) (p = 0.04; data 
not shown). The time to molecular response 3 (MR3) (BCR-ABL1/ABL1IS ratio of ≤0.1%) 
and time to molecular response 4.5 (MR4.5) (BCR-ABL1/ABL1IS ratio of ≤0.0032%, in the 
 
presence of at least 31,623 control ABL1 transcripts) are shown in Figure 5. The diagnostic 
CIP2A level, therefore, did not correlate with time to molecular response, either overall or 
for imatinib or dasatinib recipients alone. 
 
Figure 5. Time to molecular response— molecular response 3 (MR3) and molecular response 4.5 (MR4.5). Panels (a–c): 
Kaplan–Meier curves for time to MR3, stratified by diagnostic CIP2A level for (a) all 172 patients, (b) imatinib recipients, 
and (c) dasatinib recipients. Panels (d–f): Time to MR4.5 stratified by diagnostic CIP2A level for (d) all 172 patients, (e) 
imatinib recipients only, and (f) dasatinib recipients only. p-values were determined using the log-rank (Mantel–Cox) test; 
p-values are shown where significant. 
3.5. Prognostic Value of CIP2A/PP2A Related Proteins at Diagnosis 
CIP2A exerts its effects through association with a number of network-related 
proteins 31-33. These include PP2A itself 14, SET 34, SETBP1 16, 17, and S473 phosphorylation 
of AKT 17. We investigated the prognostic value of these CIP2A/PP2A-related proteins at 
diagnosis. Patients with a high SET protein level had inferior freedom from progression 
(p = 0.01, data not shown) and a trend towards inferior progression-free survival, 
compared to patients with low diagnostic SET levels. In AML, high expression of SETBP1 
at diagnosis is a marker of poor survival [14], and we have recently shown that high 
diagnostic levels of AKTS473 at diagnosis are also associated with poor outcome 17. Here 
the diagnostic level of SETBP1 did not offer any prognostic value, and although high 
levels of total AKT protein were associated with an inferior time to molecular response 2 
(MR2) for dasatinib-treated patients (p = 0.05), no prognostic significance for AKTS473 was 
found. We therefore conclude that the levels of these CIP2A-related proteins offer no 
advantages over CIP2A itself in predicting outcome in CML. 
4. Discussion 
Here we examine diagnostic CIP2A levels in a large clinical trial and demonstrate 
that high CIP2A levels are associated with a significantly higher probability of disease 
progression. However, in contrast to our previous studies (where we were unable to 
comment on dasatinib recipients as none progressed), this relationship between CIP2A on 
progression was not seen in imatinib recipients. This may be because a higher proportion 
of the present imatinib recipients switched treatment because of resistance than dasatinib 
recipients, and the rate of stem cell transplantation was five-fold higher for imatinib 
 
recipients than dasatinib recipients in the trial overall 28, and these treatment alterations 
may have prevented disease progression. This requires further study. 
The present data also indicate that high CIP2A is associated with a higher chance of 
treatment failure for both imatinib and dasatinib recipients. Higher levels of CIP2A are 
associated with a higher degree of PP2A inhibition and are known to confer treatment 
resistance in a wide range of other tumours (reviewed in 35). Little is known about CIP2A’s 
mechanism of action. A direct interaction for CIP2A and PP2A has been described, 
showing CIP2A binds at least two PP2A regulatory subunits, β56γ and β56α 36. The 
structure of the N-terminal region (residues 1–560) of CIP2A has been determined. This 
region is important in facilitating PP2A binding, as it contains the homodimer contacts 
spanning residues 507–559 that enhance CIP2A’s binding to PP2A subunits. The 
minimum region required for CIP2A binding to β56α and β56γ has been identified as 
residues 159–245 36; however, a structure containing both CIP2A and PP2A components 
has yet to be identified. Whether these interactions fulfil all CIP2A binding is unknown 
as, despite efforts by us and others, the full-length protein is unstable and has not yielded 
any crystals for X-ray crystallographic structural study. 
A plausible explanation for the adverse effects of CIP2A on treatment outcome may 
be that patients whose disease is set to have a particularly high level of PP2A inhibition 
are already destined to respond less well to treatment and are at greater risk of the 
additional genetic events required for disease progression. Junttila et al. 37 first described 
that CIP2A associates with and stabilises MYC in Hela cells, increasing MYC’s half-life 
and its activation (indicated by phosphorylation on serine 62) as well as promoting MYC 
localisation to nuclear lamins in cancer cell lines 37-40. Furthermore, in the CML cell line 
K562 19, 41 and primary CML patient cells 27, 42, we have confirmed this association. High 
levels of MYC are known to promote genetic instability and aneuploidy and thus may 
contribute to disease progression. We have previously shown that MYC inhibition can 
inhibit CIP2A via a positive feedback loop 27, 42. This interaction is direct and involves the 
N-terminal residues 1–262 of MYC. The mechanism for CIP2A’s regulation on MYC is 
likely through its inhibitory effect on PP2A-mediated MYC dephosphorylation (which 
inactivates MYC and decreases its stability). However, CIP2A may also have additional 
actions. In separate work, we have recent evidence that one mechanism of CIP2A action 
is to alter the balance of pro- and anti-apoptotic proteins in favour of creating an anti-
apoptotic phenotype 43. Furthermore, CIP2A augments oxidative phosphorylation and 
decreases reliance on glycolysis, directly interacting with a number of energy metabolism 
proteins in a manner suggesting that these metabolic effects may be mediated through 5’ 
adenosine monophosphate-activated protein kinase (AMPK), since modifying AMPK 
activity mimics the effects of CIP2A on energy metabolism 41. These metabolic effects 
appear to be a novel action of CIP2A in malignancy. 
5. Conclusions 
In summary, this study on a large, unselected trial cohort is in line with our earlier 
observations on selected local patients 19, 27 and suggests that diagnostic CIP2A protein 
levels could be used at diagnosis as a potential biomarker for predicting progression and 
treatment failure. 
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